India’s Patent Manual leaves questions unanswered

India’s Patent Manual leaves questions unanswered

The final version of India’s long-awaited Patent Manual has failed to clarify some of the grey areas in the country’s patent system

India’s IP Office published the final Manual of Patent Practice and Procedure on March 25, three years after a draft was first circulated for comment.

“They have just put the Act and the Rules together – we were waiting for certain guidelines,” said Ranjna Mehta-Dutt, a partner of Remfry & Sagar in Gurgaon.

Although praising the greater accessibility of the Manual, which is available in HTML and PDF formats, practitioners are disappointed not to have more clarity over the assessment of inventive step and unity of invention, the applications of the exceptions to patentability and the working pre-grant opposition process.

On inventive step, the manual states: “’Inventive step’ means a feature of an invention that involves technical advance as compared to the existing knowledge or having economic significance or both and that makes the invention not obvious to a person skilled in the art.”

Mehta-Dutt contrasted this with more extensive EPO guidelines on its problem-solution approach: “There are no detailed guidelines here on how examiners will assess inventive step”.

On unity of invention, Sanjay Kumar, a partner of Lakshmi Kumaran & Sridharan, gave cautious praise for the use of eight examples in the manual of how claims in different categories may relate to a single inventive concept: “These may be helpful, but these should not be used as limiting examples.”

Section 3 of India’s Patent Act lists a series of exceptions to patentability. These include Section 3(d), which states that “the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance” is not patentable.

The Manual quotes from a 2007 Madras High Court decision in the long-running battle Novartis has waged to patent its anti-cancer blockbuster drug Glivec. That decision restricts the definition of efficacy to therapeutic efficacy, which pharmaceutical companies believe is too restrictive.

Patent practitioners had advised the Patent Office not to quote from this decision as the Madras decision has been appealed to the Supreme Court, which is due to hear the case later this month. Patent owners are worried that it might take too long to update the Manual to reflect any new definition produced by the Supreme Court.

Section 3(k) of the Patents Act excludes software programmes “per se” from patentability. Three years ago the circulations of the draft manual led to protests from campaigners for open source software, who felt this was being interpreted too loosely. This section has now been substantially revised.

Under Section 3(k) mathematical methods, business methods, computer programmes per se and algorithms are not considered patentable.

An algorithm is defined in the manual as “a set of rules or procedures or any sequence of steps or any method expressed by way of a finite list of defined instructions, whether for solving a problem or otherwise”.

Gabriel said that this definition is too broad: “Saying that an algorithm is a step-by-step method means that it could apply to mechanical inventions.”

The manual goes on to further restrict how per se can be defined: “Claims directed at ‘computer programme products’ are computer programmes per se stored in a computer readable medium and as such are not allowable”.

Patent applicants in India also face the problem of the patent system allowing both pre- and post-grant oppositions. At present, pre-grant oppositions can be filed at any time between filing and grant and the opposer does not need to show any material interest in the patent or pay a fee.

This has led to serial oppositions, particularly against pharmaceutical patents. Mehta-Dutt had been hoping for more clarity: ‘There are no clear guidelines as to how examiners will handle pre-grant oppositions,” she said.

Gabriel said that such pre-grant oppositions should be restricted to a three- or four- month window after publication, but that this change should be made through amendments to the Patents Act in Parliament, not in the Manual.

The Office of the Controller General of Patents, Designs and Trade Marks has also published the final version of its Manual of Designs Practice and Procedure. Comments can still be submitted on a draft GI Manual.

more from across site and SHARED ros bottom lb

More from across our site

Varuni Paranavitane says she is excited to bring ‘rounded expertise’ to the firm, which will have a solicitor in its ranks for the first time
Lawyers adapting to AI-driven recommendations are being pushed to demonstrate expertise publicly rather than simply relying on a polished website
Mid-market businesses looking to establish an online presence need ‘holistic’ brand protection services at an accessible cost, according to partners
Our latest update also includes the latest case filing statistics, and an update on how a transatlantic merger could be a UPC opportunity for the US half of the partnership
New partners, from biotech company Leyden Labs and Novartis, take the total number of partner hires to 12 since the firm took on external investment in late 2024
Labelled the ‘largest law firm merger in history’, the new outfit could also spell an opportunity for US clients to capitalise on Hogan Lovells' UPC expertise
Andy Lee and Amy Brooks of Brandsmiths explain how the firm secured a win for Peppa Pig over rival children’s character Wolfoo, in a case that centred on copied audio clips
Pedro Moreira outlines proposals by INPI that look set to open a discussion regarding biological materials, extracts, sequences, genetically edited plants, and computer programs
The combined firm, which has a newly appointed IP partner in London, brings together more than 3,500 practitioners across 52 offices, with flagship hubs in Seattle, London, Sydney and New York
A host of SEP-rich law firms, both leading arguments and as intervenors, are set to feature in the UK Supreme Court’s third FRAND episode, though one ground of appeal has been settled
Gift this article